We are live on ! Find out more
TARO

Taro Pharmaceutical Industries Ltd.

Delisted

TARO was delisted on the 21st of June, 2024.

139 hedge funds and large institutions have $712M invested in Taro Pharmaceutical Industries Ltd. in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 55 increasing their positions, 45 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 45

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

3% less capital invested

Capital invested by funds: $731M → $712M (-$19M)

8% less funds holding

Funds holding: 151139 (-12)

25% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 20

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1.5M

Holders
139
Holders Change
-12
Holders Change %
-7.95%
% of All Funds
3.46%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.1%
New
15
Increased
55
Reduced
45
Closed
20
Calls
Puts
$1.5M
Net Calls
-$1.5M
Net Calls Change
-$1.03M

TARO Hedge Fund Activity: Q1 2017 in Review

139 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q1 2017, worth a combined $712M — down 2.6% from $731M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of TARO and 15 opened new positions — a net loss of 5 holders — while 45 trimmed existing stakes and 55 added.

The largest buyer was BlackRock, adding an estimated $53.9M. The largest seller was Renaissance Technologies, cutting an estimated $26.7M.

  • 139 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q1 2017, down from 151 in Q4 2016.
  • Funds reported $712M of Taro Pharmaceutical Industries Ltd. stock for Q1 2017, down 2.6% quarter-over-quarter.
  • 15 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q1 2017 and 20 closed out, a net change of -5 holders.
  • The largest Taro Pharmaceutical Industries Ltd. buyer in Q1 2017 was BlackRock, an estimated $53.9M added.
  • The largest Taro Pharmaceutical Industries Ltd. seller in Q1 2017 was Renaissance Technologies, an estimated $26.7M sold.

Based on aggregated 13F filings for Q1 2017.